Загрузка...
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advance...
Сохранить в:
| Опубликовано в: : | Nat Rev Urol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532875/ https://ncbi.nlm.nih.gov/pubmed/27324121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrurol.2016.103 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|